At AI|ffinity, we are pioneers in leveraging the synergy of Nuclear Magnetic Resonance (NMR) 🧲 and Artificial Intelligence (AI) 🧠 to forge unprecedented pathways in drug development. We target a wide array of proteins, including those considered previously undruggable, such as intrinsically disordered proteins (IDPs). We are particularly interested in collaborations involving pre-clinical drug development (hit identification, lead optimization, preclinical candidate selection) or antibody design.

✅ Unique Selling Proposition

● 🧲🧠NMR-AI Synergy for Drug Discovery : We leverage proprietary NMR experiments in every stage of drug discovery, bolstered by our AI and cheminformatics tools. These tools utilize 1D NMR screening data to boost AI-driven drug design and accelerate 3D structure calculations with our ML-based 4D NMR method.

●  📈 Unrivaled Drug Screening: We can screen around 1500 molecules daily through photo hyperpolarized 1D NMR, which is backed by our AI tools. By managing protein concentrations at ~1 μM and compounds at ~10 μΜ, our approach is ideal for proteins prone to aggregation and weak inhibitors (e.g. hit compounds), a unique feature in the market.

● 🌐 Ideal for All Proteins, including IDPs & Aggregating ones: Given that NMR stands as the top choice for studying the structure and interactions of intrinsically disordered proteins (IDPs) with other molecules, our combined NMR-AI approach is ideally suitable for them and other proteins that tend to aggregate. These proteins cover over 30% of the eukaryotic proteome. 

● ⚡💶 Rapid & Cost-Efficient Protein(-Ligand) Structure Determination: Our unique 4D NMR technology determines the structures of protein or proteins in complex with drug candidates in a manner that's 60% faster and more cost-effective than traditional NMR methods. Additionally, it's up to 6x faster and 3x times more affordable than X-ray crystallography, which is the method of choice in the industry.

🤝 Opportunities for Collaboration:

🏛🔬 Academic and Industrial Synergy: As a spin-off from Masaryk University (Brno, Czech Republic), we have privileged access to the Central European Institute of Technology (CEITEC) fully-fledged biophysical facilities for our joint drug discovery and bioengineering projects with industrial or academic partners.

👥 Joint Asset Development: We seek collaborations for joint drug and antibody development projects.

🔧 Method and Software Development: Proposals for joint method and software development focused on drug design or NMR structure determination are also welcomed.

📩 Invitation to Partner: If you would like to collaborate with AI|ffinity, please provide us with a non-confidential proposal along with scientific supporting data in your application.